RBTI yields 3333333.33% · ABBV yields 3.06%● Live data
📍 RBTI pulled ahead of the other in Year 1
Combined, RBTI + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of RBTI + ABBV for your $10,000?
Red Branch Technologies, Inc., a technology holding company, engages in the development and commercialization of security and defense industry solutions. It offers The Mini that supports a combination of applications, such as mesh networks; The Mojo, which supports various applications, including video surveillance and long distance communications, as well as mesh networks; and The Titan that supports heavy amp applications, such as ground radar, thermal imaging, or satellite uplink for mobile security solutions. The company also provides TeleMax, tEODor-Robust bomb disposal robot, ODIS-T2 for omni-directional inspection, and multi-mission next generation ODIS-T2 for ordinance disposal and inspection. In addition, the company offers unmanned aerial vehicles, such as Long Star and XTS UAV for aerial surveillance. Its products are used in various applications, including disaster recovery; physical security; border, pipeline, and perimeter; wireless communication nets; forward operating bases; event security; humanitarian services; and water desalination, purification, pumping, as well as in military and law enforcement, and industrial-security/safety organizations. The company was incorporated in 1987 and is based in Ashburn, Virginia.
Full RBTI Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.